#OPENLABEL
LightNews LightNews
throwable.bsky.social
📦 iranimij/openlabel v1.1.1

OpenLabel: product labels for Magento 2 and Hyvä. Rule-based labels with a dedicated indexer, zero layout shift, full page cache safe. Free and MIT.

🔗 https://github.com/iranimij/openlabel
October 15, 2026 at 4:00 PM
throwable.bsky.social
📦 iranimij/openlabel v1.0.0

OpenLabel: product labels for Magento 2 and Hyvä. Rule-based labels with a dedicated indexer, zero layout shift, full page cache safe. Free and MIT.

🔗 https://github.com/iranimij/openlabel
October 11, 2026 at 10:21 PM
throwable.bsky.social
📦 iranimij/openlabel-hyva v1.0.0

OpenLabel render package for Hyvä themes: label slots in product listings and the product gallery, generated per-store CSS, no Tailwind rebuild needed.

🔗 https://github.com/iranimij/openlabel-hyva
October 11, 2026 at 10:21 PM
throwable.bsky.social
📦 iranimij/openlabel-hyva-bundle v1.0.0

OpenLabel for Hyvä in one require: product labels for Magento 2 and Hyvä (core, Hyvä render package and the shared base module). Free and MIT.

🔗 https://github.com/iranimij/openlabel-hyva-bundle
October 11, 2026 at 10:21 PM
akornsys-rdi.net
I'll keep an eye on openlabel to see what I can find, thanks!
April 30, 2025 at 9:52 AM
tom-doerr.bsky.social
https://github.com/Dwarf1er/openlabel
April 12, 2026 at 11:13 AM
cscv-bot.bsky.social
dataset contains six object classes and is provided in the OpenLABEL format. We propose an accident detection model that combines a rule-based approach with a learning-based one. Experiments and ablation studies on our dataset show the robustness of [4/5 of https://arxiv.org/abs/2503.12095v1]
March 18, 2025 at 5:58 AM
bibliotecahuvh.bsky.social
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage,triple-negative breast cancer: exploratory analysis of openlabel,multicohort phase 1b... breast-cancer-research.biomedcentral.com/articles/10.... #hvhebron #onco [Text complet]
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multic...
Background The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This ex...
breast-cancer-research.biomedcentral.com
March 13, 2025 at 3:30 PM
wiranyasu.bsky.social
มารอมุแล้วคับ 🦖

#รสดีหม่าล่าพาฟินกับต้าห์อู๋
#รสดีซุปก้อนHotpotรสซุปหม่าล่า
#MALASTATION
#DAOU
#OPENLABEL
October 19, 2024 at 9:43 AM
skiesofpluto.bsky.social
a more budget model... it's called a nelko altho i think a few brands sell identical machines. 203 dpi, i use an app called OpenLabel to print
October 13, 2025 at 10:15 PM
epsteinweb.bsky.social
Parts 1-3/3 — EFTA01155958.jpg
#epsteinweb #efta01155958
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01155955 | EFTA01155958 Placebos without Deception and 37 into open-label placebo). There were missing outcome data for 13 patients at midpoint (16%; 6 no-treatment control, 7 openlabel placebo), and for 10 patients at endpoint (13%; 4 notreatment control, 6 open-label placebo). As noted above, missing data was replaced using the last observation carried forward method. Table 1 shows baseline data. As shown in Figure 2 and Table 2, patients treated with openlabel placebo had significantly greater scores than the notreatment control on the main outcome measure, Global Improvement Scale (IBS-GIS), at both the II -day midpoint (5.2±1.0 vs. 4.0±1.I, /K.001, d= 1.14) and the 21-day endpoint (5.0±1.5 vs. 3.9±1.3, y=.002, d= 0.79). In addition, there were statistically significant differences at both time points on reduction on in symptom severity (IBS-SSS) and adequate relief (IBS-AR), and a trend toward significance at the 2I-day endpoint on improvement in quality of life (IBS-QO1.). Forty-three patients saw the male physician for all three visits, 20 patients saw the female nurse-practitioner for all three visits, and 17 patients saw a combination of the two or missed a treatment session. Given that the two treatment providers differed by gender and discipline (MD vs. NP), we tested for differences in treatment outcomes. No significant differences were found between providers on the primary outcome measure, IBS-GIS (p = .57 at midpoint, and p = .51 at endpoint). Similarly, there were no significant differences between providers on any of the secondary outcome measures. Adverse events were reported by only three placebo-treated patients (8%) at midpoint and five patients (14%) at endpoint. The most common adverse events that patients reported were upper respiratory infection (N = 3) and pain (N = 2); other events included rash, runny stools, and a sty on the eye. The detailed results of the qualitative check-out questionnaire will be reported elsewhere. However, responses to two questions seemed especially relevant to the interpretation of this quantitative report. Specifically, I) did patients in the open-label arm understand that they were taking a placebo ("What did you think was in the placebo pills?") and 2) were patients in the no treatment arm disappointed ("Were you disappointed to be in the treatment as usual arm?") To answer these questions two researchers (UK, MK) independently extracted the responses to these questions. A third researcher compared these extracted responses and a discussion settled two occasions where handwriting that was difficult to interpret. TJK categorized the data using the iterative and emergent methodology of grounded theory. [25,26] When participants in the placebo arm were asked: " What did you think was in the placebo pills?" of the 29 who responded, 16 wrote "sugar" (12), "flour" (3) or "calcium" (I)," 6 responded "nothing," 5 responded "did not know," 1 responded "symbolic reminder," and I responded "possible test medication." When participants in the no-treatment ann were asked: "Were you disappointed to be in the treatment as usual arm?" of the 38 who responded, 29 said "no" and only 9 said "yes" or "a little". We then looked at the responses of the nine who expressed disappointment, to see how they responded to: "What did you like most and least about the trial?" All gave uniformly positive answers such as "I liked that my feeling about the intensity of the problem was validated and was taken seriously...and was able to discuss my IBS," "the doctor and the nurse were wonderful and accommodating," "I liked the one-on-one attention with the MD, able to ask questions about IBS with a person trained in the illness; this MI) is yen. kind" (underling in the original). This qualitative data seemed to indicate that, in general, patients understood they were taking placebo and were not overly disappointed in being in the no-treatment arm. gps) Discussion We found that patients given open-label placebo in the context of a supportive patient-practitioner relationship and a persuasive rationale had clinically meaningful symptom improvement that was significantly better than a no-treatment control group with matched patient-provider interaction. To our knowledge, this is the first RCP comparing open-label placebo to a no-treatment control. Previous studies of the effects of open-label placebo treatment either failed to include no-treatment controls [27] or combined it with active drug treatment. [28] Our study suggests Table 1. Demographics and Baseline Characteristics. Demographics end Baseline Characteristics No Treatment (N=43) Open Placebo (N=37) Age Female - no. (r...6) 46118 32 (74) White - no. (16) IBS Type - no. CM 36 (84) 47-118 24 (65) 26 (70) Diarrhea Predominant 16 (37) 10 (27) Constipation Predominant Mixed 14 (33) 13 (30) 16 (43) 11 (30) Ns Duration in Years Symptom Severity (IBS-SSS) 13111 297-1-58 16112 310-s82 Quality of Life 0BSCIOL) Upper GI Symptoms (GERD & Dyspepsia) - no. (96) Taking Medications for IBS - no. (%) 59121 55121 18 (42) IS (35) 11 (30) 20 (M) Taking Antidepressants - no. (96) 7 (16) 9 (24) Note: All values are means L-SD. rats otherwise noted. Group differences were examined using Independent t-tests for continuous measures and chi square test for categorical measures_ IBS = Irritable bowel syndrome; IBS-5S5 = IBS Symptom Severity Scale; IBSQ0L = IBS Quality of Life Scale; GI = Gastrointestinal; GERD = Gastroesophageal Reflux Disease. dok10.137ujournalpone.00t5S91.t00l f6, PLoS ONE I www.plosone.org 4 December 2010 I Volume 5 I Issue 12 I e15591 EFTA01155958
May 12, 2026 at 8:34 AM
thatgirllainie.bsky.social
Sound check for Daou’s event : Amazing Music Festival Over The Horizon)

Cr. OpenLabel-th on the X

#Daou #ต้าห์อู้ #Oueija
September 1, 2024 at 4:12 AM
chengdulittlea.bsky.social
I eventually used "OpenLabel" APP and it worked with some minimal issue but I don't need to have to deal with that nonsense. I feel bad for regular customers that has to go through all these hassle and pay much more to those greedy companies...
January 24, 2025 at 1:56 PM
k.layer8.space.ap.brid.gy
ah it just shows up as a Openlabel 58MM Printer!
how handy.
June 24, 2026 at 4:53 PM
fabienb.bsky.social
OpenLabel: Exchange product information with a scan. via @BetaList

btl.st/LP9WF8
November 26, 2024 at 10:13 AM
clomads.bsky.social
there seems to be a handful ofgeneric protocols and some using proprietary protocols. I've been using a free app on iphone called openlabel.... I have seen some linux support, but i haven't looked that deep
April 29, 2025 at 11:59 PM
suxin.bsky.social
หยุดตรงสเปคกี่โมง
#รสดีหม่าล่าพาฟินกับต้าห์อู๋
#รสดีซุปก้อนHotpotรสซุปหม่าล่า
#MALASTATION
#DAOU
#OPENLABEL
October 19, 2024 at 2:31 PM
ghostrider3174.bsky.social
#Repost @openlabel_th
ขอบคุณ @off____white ที่ชวนออฟโรดมาสนุกกับคอลเลคชั่นใหม่
Off-White™ Winter 2024 Styling Session ในวันนี้นะครับบ ❤️

OFFWHITE x OFF ROAD
#OffWhite
#OFFWHITEWINTER2024xOFFROAD
#OffWhiteBangkok #OffWhiteCommunity
#OPENLABEL
October 19, 2024 at 2:13 PM
doeusaengdao.bsky.social
Place this poster here to start turning this account into a place to store my collected images, along with my own random designs. Tell yourself, "I have to be more diligent!"🫶🏻

❤️🦖🚗
OUROAD UPCOMING PROJECT
#ต้าห์อู๋ออฟโรด
#ต้าห์อู๋ออฟโรดวันสนั่นจอ2025
#TheWickedGameSeries
#oneสนั่นจอ2025
#OPENLABEL
October 18, 2024 at 2:07 PM
tpopbr.bsky.social
🛣️ Foi lançado hoje o mv de "ผิดแผน (FOUL)", single de comeback de Offroad { #offroadKTP}. O single tem a colaboração de #SMEW!

🔗 youtu.be/OqUG1xgn-I4

#OFFROAD_ผิดแผนMV #OFFROAD_ผิดแผน
#onemusic #OPENLABEL
#tpop #tpopbr
February 25, 2025 at 1:21 PM
tpopbr.bsky.social
📸| O mv de "ผิดแผน (FOUL)", single de comeback de Offroad { #offroadKTP #OFFROAD} que tem a participação de #SMEW, será lançado dia 25 de Fevereiro.

#OFFROAD_ผิดแผน #onemusic #OPENLABEL
#tpop #tpopbr
February 21, 2025 at 8:50 PM
tpopbr.bsky.social
🎁| Já está disponível a colaboração de #Daou, Porsche { #XXSIVK}, Nice { #NiceATLAS}, Gun { #PROXIEGun} e Jung { #JUNG_PERSES} para "ละลาย (LALALYE)".

Assista!
🔗 youtu.be/kHpgcGcBljU

#DAOU_ละลาย #ละลาย_SPECIALCOLLAB
#OPENLABEL #tpop
#tpopbr
December 25, 2024 at 11:53 AM
tpopbr.bsky.social
📸| A colaboração especial de "ละลาย (LALALYE)" de #DAOU, que traz Porsche { #XXSIVK}, Nice { #NiceATLAS}, Gun { #PROXIEGun} e Jung{ #JUNG_PERSES}, será lançada dia 24 de Dezembro.

#DAOU_ละลาย #OPENLABEL
#tpop #tpopbr
December 23, 2024 at 4:53 PM
tpopbr.bsky.social
🎶 Já está disponível o mv de "ละลาย (LALALYE)", novo single de Daou Pittaya { #DAOU}!

Assista:
🔗 www.youtube.com/watch?v=wo6r...

#DAOU_ละลายMV #DAOU_ละลาย
#onemusic #OPENLABEL
#tpop #tpopbr
November 28, 2024 at 11:44 AM
tpopbr.bsky.social
📸| ITI MALIAS!

Nova postagem da Open Label { #OPENLABEL} traz Daou e Offroad { #DaouOffroad} em Macau.

Iti iti iti 😍😍😍

#tpop #tpopbr
September 20, 2024 at 2:07 PM